Professional Resources Close Menu. Announcements Show. Acute hypersensitivity reactions, including dyspnea, rash, pruritus, and angioedema of the mouth, throat, and face have been reported with DIFICID. DIFICID is not expected to be effective for the treatment of other types of infections due to minimal systemic absorption of fidaxomicin.
|Published (Last):||25 April 2011|
|PDF File Size:||17.74 Mb|
|ePub File Size:||13.9 Mb|
|Price:||Free* [*Free Regsitration Required]|
Check with your pharmacy to learn what features they offer to patients. Merck does not support the use of any particular pharmacy, and one is not preferred over the others. Merck does not make any warranty as to the features and support offered by any particular pharmacy. Professional Resources Close Menu. Announcements Show.
Patient support features may include: Information and assistance regarding access to therapy including benefits investigation and reimbursement requirements Product availability Expedited delivery of medications after any prior authorization, if required, is approved Disease-related educational materials for patients DIFICID is available at pharmacies in and out of the network. Find network pharmacies. Acute hypersensitivity reactions, including dyspnea, rash, pruritus, and angioedema of the mouth, throat, and face have been reported with DIFICID.
DIFICID is not expected to be effective for the treatment of other types of infections due to minimal systemic absorption of fidaxomicin. Vomiting was the primary adverse reaction leading to discontinuation of dosing incidence of 0. The recommended weight-based dosage of the oral suspension in pediatric patients weighing at least 4 kg is twice daily for 10 days.
No dose adjustment is recommended for patients with renal impairment. No dosage adjustments are recommended when co-administering fidaxomicin with substrates of P-gp or CYP enzymes.
The impact of hepatic impairment on the pharmacokinetics of fidaxomicin has not been evaluated; however, because fidaxomicin and its active metabolite OP do not appear to undergo significant hepatic metabolism, elimination of fidaxomicin and OP is not expected to be significantly affected by hepatic impairment. The Patient Information also is available. Indication Selected Safety Information.
Selected Safety Information